Pharmaceuticals News and Research

RSS

Interest groups campaign against proposed health taxes

"Insurance companies, unions, medical device makers and others in the health care industry are furiously lobbying lawmakers to shift burdens onto someone else — anyone else — before they find themselves saddled with billions of dollars in taxes under new health care legislation," The Associated Press reports.

15 Oct 2009

Institute of Medicine elects two new members from St. Jude Children's Research Hospital

Michael Kastan, M.D., Ph.D., and Mary Relling, Pharm.D., of St. Jude Children's Research Hospital, have been elected to the Institute of Medicine (IOM), a prestigious branch of the National Academy of Sciences.

15 Oct 2009

Jazz Pharmaceuticals to present Phase III sodium oxybate trial data at ACR 2009 meetings

Jazz Pharmaceuticals, Inc. announced that data from the company's first Phase III clinical trial of sodium oxybate (JZP-6) for the treatment of fibromyalgia will be presented during the American College of Rheumatology 2009 Annual Meeting (ACR) in Philadelphia, Pennsylvania and also in November during the US Psychiatric and Mental Health Congress (US Psych Congress) in Las Vegas, Nevada.

15 Oct 2009

Healthways announces acquisition of behavioral economics company, HealthHonors

Healthways, Inc. today announced the acquisition of HealthHonors, a market-leading behavioral economics company that specializes in behavior change science and optimized use of incentives, in a cash for stock transaction.

15 Oct 2009

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.

15 Oct 2009

Fero Industries to acquire Pyro Pharmaceuticals

Fero Industries, Inc. (the “Company”) is pleased to announce that the Company has entered into a Definitive Agreement to acquire Pyro Pharmaceuticals, Inc. of Irvine, California.

15 Oct 2009

APN and Cardinal Health sign agreement to help improve practice operations

Aesyntix Physician Network (APN), a leading national group purchasing organization (GPO) for dermatologists and plastic surgeons, today announced it has signed an agreement with Cardinal Health to provide APN members with products and services designed specifically for dermatologists and plastic surgeons.

15 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Progenics Pharmaceuticals, Inc. today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth under which Progenics is regaining all worldwide rights to the RELISTOR® franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to Wyeth Pharmaceuticals.

14 Oct 2009

Delegation from All-CABPA visits Sundia

A delegation from the Alliance of Chinese-American Biotechnology and Pharmaceutical Associations (All-CABPA) visited Sundia in Shanghai's famous Zhangjiang Hi-Tech Park on October 12.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

European Patent Office to grant two intellectual property patents to Athera Biotechnologies

Athera Biotechnologies AB, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), announced today that the European Patent Office intends to grant two key patents related to the Company's intellectual property on its two pharmaceutical candidates Annexin A5 and PC-mAb.

14 Oct 2009

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced that a presentation on L-DOS47 formulation and analytical method development will be made at the "Formulation Strategies for Protein Therapeutics" conference to be held on October 13 to 15, 2009, in Raleigh, North Carolina. The conference is sponsored by IBC Life Sciences.

14 Oct 2009

OSUCCC-James and Global Vision Technologies collaborate to deliver a web-based patient registry solution

The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) has entered into a contract with Global Vision Technologies (GVT) to create and deliver a new, web-based Photo Dynamic Therapy patient registry solution -- ClinicalPURSUIT -- to help streamline the data collection and outcomes analysis process.

14 Oct 2009

HTDS to release its next 90 to 180 day forward guidance report

HTDS www.htdsmedical.com - The Company intends to release its next 90 to 180 day forward guidance concurrent with its profile launch on www.stockprofile.com .

14 Oct 2009

Antisense Therapeutics completes repeat-dosing toxicology studies for ATL1103

Antisense Therapeutics Limited is pleased to announce that the Company has now completed repeat-dosing toxicology studies for ATL1103 in two species -- mouse and non-human primate. Draft study reports from the study contractors in the United States have been received, and the toxicology outcomes from these studies support ANP's plans for the continued development of ATL1103.

14 Oct 2009

AAPS to present eLearning Webinar on Nanotechnology in Drug Design and Development

The American Association of Pharmaceutical Scientists (AAPS) is a professional, scientific society of approximately 12,000 members employed in industry, academia, government and other research institutes worldwide.

14 Oct 2009

2010 TIPPS certification for Prime Therapeutics

Prime Therapeutics (Prime), a thought leader in pharmacy benefit management, has met high standards of pharmacy cost transparency, earning it 2010 Transparency in Pharmaceutical Purchasing Standards(SM) (TIPPS) certification from the HR Policy Association.

14 Oct 2009

Prime Healthcare Services renews its supply chain relationship with Broadlane

Broadlane, the leading cost-management company for healthcare providers, announced today that Prime Healthcare Services in Victorville, California has renewed its supply chain relationship with Broadlane for another five years.

14 Oct 2009